134 related articles for article (PubMed ID: 34832908)
1. Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells.
Boulos JC; Saeed MEM; Chatterjee M; Bülbül Y; Crudo F; Marko D; Munder M; Klauck SM; Efferth T
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832908
[TBL] [Abstract][Full Text] [Related]
2. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
Zhang S; Wang F; Keats J; Zhu X; Ning Y; Wardwell SD; Moran L; Mohemmad QK; Anjum R; Wang Y; Narasimhan NI; Dalgarno D; Shakespeare WC; Miret JJ; Clackson T; Rivera VM
Chem Biol Drug Des; 2011 Dec; 78(6):999-1005. PubMed ID: 22034911
[TBL] [Abstract][Full Text] [Related]
5. In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia.
Boulos JC; Chatterjee M; Shan L; Efferth T
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627164
[TBL] [Abstract][Full Text] [Related]
6. Chemometric and Transcriptomic Profiling, Microtubule Disruption and Cell Death Induction by Secalonic Acid in Tumor Cells.
Özenver N; Dawood M; Fleischer E; Klinger A; Efferth T
Molecules; 2020 Jul; 25(14):. PubMed ID: 32679716
[TBL] [Abstract][Full Text] [Related]
7. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
8. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Katayama R; Khan TM; Benes C; Lifshits E; Ebi H; Rivera VM; Shakespeare WC; Iafrate AJ; Engelman JA; Shaw AT
Proc Natl Acad Sci U S A; 2011 May; 108(18):7535-40. PubMed ID: 21502504
[TBL] [Abstract][Full Text] [Related]
11. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer.
Bland AR; Bower RL; Nimick M; Hawkins BC; Rosengren RJ; Ashton JC
Eur J Pharmacol; 2019 Dec; 865():172749. PubMed ID: 31654622
[TBL] [Abstract][Full Text] [Related]
14. Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma.
Boulos JC; Omer EA; Rigano D; Formisano C; Chatterjee M; Leich E; Klauck SM; Shan LT; Efferth T
Acta Pharmacol Sin; 2023 Nov; 44(11):2265-2281. PubMed ID: 37344563
[TBL] [Abstract][Full Text] [Related]
15. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
Dai Y; Wei Q; Schwager C; Moustafa M; Zhou C; Lipson KE; Weichert W; Debus J; Abdollahi A
Radiother Oncol; 2015 Feb; 114(2):173-81. PubMed ID: 25592111
[TBL] [Abstract][Full Text] [Related]
17. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
18. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
19. STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.
Cuyàs E; Pérez-Sánchez A; Micol V; Menendez JA; Bosch-Barrera J
Cell Cycle; 2016 Dec; 15(24):3413-3418. PubMed ID: 27753543
[TBL] [Abstract][Full Text] [Related]
20. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]